- YOU just donated $10.50
- Stephen just donated $525
- Robert just donated $52.50
- Leonard just donated $52.50
- Susan just donated $105
- Daniel just donated $210
- Atilio just donated $26.25
- Moira just donated $26.25
- Darryl just donated $26.25
- Maurice just donated $525
- Knut just donated $157.50
- Carlos just donated $52.50
- Zlatko just donated $26.25
- Donald just donated $100
- Andrew just donated $50
- Anthony just donated $100
- Warren just donated $25
- Greg just donated $52.50
- Shane just donated $157.50
- Kiefeng just donated $26.25
The RBWH Foundation needs your help to raise funds for groundbreaking
prostate cancer immunotherapy research.
In Australia, more men die of prostate cancer than women die from breast cancer.
Prostate cancer is the most diagnosed cancer in men, killing approximately 3,500 Australians each year. This cancer does not produce symptoms until it is advanced, so early diagnosis is currently made indirectly through the PSA blood test.
- One in 7 men will be diagnosed with prostate cancer by the age of 85.
- While it is more common in older men, younger men also get prostate cancer, with 37% of cases diagnosed in men under 65 of age.
- 30% of patients who undergo radical prostatectomy, the commonest form of treatment for clinically located disease, have secondary cancer diagnosed subsequently.
The vision of the ImmunoPro project, led by world-leading Royal Brisbane and Women’s Hospital (RBWH) researchers, is to develop a therapeutic vaccine, tailored to each prostate cancer patient. The therapeutic vaccine would use immunotherapy post prostatectomy to enhance and increase the patient’s own cancer-fighting cells, reducing the need for radiation and hormone therapy.
Previous therapeutic vaccine studies have shown very minimal side effects. This therapy has the potential to be extended to men in other advanced stages of prostate cancer, such as after initial radiotherapy, which is difficult to treat cells, reducing the need for radiation and hormone therapy.
Donate today and help RBWH researchers develop a therapeutic vaccine for all prostate cancer patients.
To read more about the ImmunoPro project please click here.
Emeritus Professor ‘Frank’ Gardiner, who initiated and ran two dendritic-cell based therapeutic vaccine trials in prostate at RBWH previously, will coordinate the project. Dr Matthew Roberts and Associate Professor John Yaxley will undertake all aspects of the clinical research at Royal Brisbane and Women’s Hospital (RBWH) with immunological studies to be performed by Associate Professor Kristen Radford at Mater Medical Research Institute/The Translational Research Institute (TRI). Associate Professor Michelle Hill from QIMR Berghofer Medical Research Institute and Dr Kevin Koo from the University of Queensland Centre for Clinical Research (UQCCR) will continue ongoing minimally invasive early detection and monitoring research on the RBWH campus with input from Dr Paul Mainwaring at Xing Technologies and Professor Matt Trau from The University of Queensland/CSIRO.
Make a Donation to Support Prostate Cancer
All donations over $2 are tax deductible